ASPEN PHARMACARE HOLDINGS LIMITED - Voluntary announcement - Aspen to launch Hydroxyprogesterone Caproate injection in the United States

Voluntary announcement - Aspen to launch Hydroxyprogesterone Caproate injection in the United States

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)
Registration number: 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
and its subsidiaries (collectively “Aspen” or “the Group”)


VOLUNTARY ANNOUNCEMENT - ASPEN TO LAUNCH HYDROXYPROGESTERONE CAPROATE
INJECTION IN THE UNITED STATES


Shareholders are referred to the voluntary announcement released on the Stock Exchange News
Service (“SENS”) on 1 December 2015 wherein it was stated that Aspen Global Incorporated
(“AGI”), a wholly owned subsidiary of Aspen Holdings, had acquired the intellectual property and
the approved Abbreviated New Drug Application in the United States in respect of the finished dose
form of Hydroxyprogesterone Caproate (“HPC”).

 Aspen is pleased to announce that AGI expects to launch the finished dose form product, indicated
for the treatment of certain female cancers and hormonal imbalances, in the United States during
its current financial year which ends on 30 June 2016. Aspen is in advanced negotiations with a
United States pharmaceutical company with proven capabilities in this category to distribute the
HPC finished dose form.

Aspen currently manufactures the active pharmaceutical ingredient (“API”) for HPC and is a
substantial supplier of HPC API to the United States. Aspen's launch of HPC injection is a realisation
of Aspen’s stated intent to develop commercial opportunities in the United States which are aligned
to the intellectual property available within the Group.

Durban
19 February 2016

Sponsor:

Investec Bank Limited

Date: 19/02/2016 12:30:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.